#USA #Boston #SOPHiA GENETICS #AI Precision Medicine #Jurgi Camblong

SOPHiA GENETICS Shows Strong Financial Growth in Q4 and Full Year 2025

SOPHiA GENETICS, a leader in AI-driven precision medicine, has recently published its preliminary financial results for the fourth quarter and the entire year of 2025. The company, listed on Nasdaq under the symbol SOPH, has reported an impressive performance that sets a positive outlook for its upcoming fiscal year.

Financial Highlights for Q4 2025

In the fourth quarter of 2025, SOPHiA GENETICS achieved revenues of at least $21 million, marking approximately a 20% increase year-over-year. This strong quarter also included over 105,000 analyses conducted using its proprietary SOPHiA DDM™ platform, reflecting a 16% annual growth. These results underscore the company's position in the rapidly evolving healthcare technology landscape, driven by increasing demand for data-driven medical insights.

Financial Overview for Full Year 2025

For the entire year of 2025, SOPHiA GENETICS reported revenues reaching nearly $77 million, translating to an 18% increase compared to the previous year. This is a significant achievement, thanks to more than 391,000 analyses performed on the SOPHiA DDM™ platform, which sets a new record for the company. Jurgi Camblong, the CEO of SOPHiA GENETICS, expressed satisfaction with the company’s growth trajectory, indicating that the results lay a solid foundation for robust growth in the years to come.

2026 Growth Forecast

Looking ahead, SOPHiA GENETICS has provided guidance for 2026, anticipating a revenue range between $92 million and $94 million. This projection indicates a healthy 20-22% growth for the year. Although the objectives also involve an anticipated adjusted EBITDA loss between $29 million and $32 million, the company remains focused on leveraging its standout product offerings, including the market-leading Liquid Biopsy application MSK-ACCESS®, to drive growth.

Executive Transition and Leadership Changes

An important aspect of the announcement included a leadership transition within the company. Ross Muken, who has served as the CFO since February 2021, has been promoted to CEO, effective July 1, 2026. Muken will succeed Jurgi Camblong, the co-founder and current CEO, who will take on the role of Executive Chairman of the Board, subject to election at the upcoming annual general meeting in June 2026.

Muken's journey within SOPHiA GENETICS has been marked by substantial contributions to the company’s growth, including overseeing global business operations and enhancing commercial execution strategies. Camblong praised Muken's capabilities, expressing confidence in his ability to lead the company through its next growth phase.

Reflections on Future Impact

Over the past fifteen years, SOPHiA GENETICS has significantly impacted the healthcare domain, democratizing data-driven medicine across over seventy countries and eight hundred healthcare institutions. By harnessing AI technology, the company aims to continue revolutionizing patient care, particularly in oncology and rare diseases. As SOPHiA GENETICS prepares for its first earnings call in 2026, scheduled for March 3, 2026, stakeholders will eagerly await final financial figures and strategic developments that could further shape the company's growth narrative.

In summary, SOPHiA GENETICS stands at a pivotal moment, with a solid performance in 2025 and promising prospects for 2026, coupled with strategic leadership changes designed to ensure continued innovation and market presence in the field of precision medicine.